[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Centre Hospitalier Universitaire de la Réunion\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":607},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,37,0,25,[9,41,67,93,121,142,161,188,217,240,259,282,304,333,366,389,410,434,457,478,501,522,542,561,581],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":4},"100054092","anti-inflammatory-effects-of-curcumin-ginger-and-piperine-supplementation-in-ultra-trail-runners-a-double-blind-randomized-placebo-controlled-trial-100054092",false,"NCT07699575","Anti-inflammatory Effects of Curcumin, Ginger and Piperine Supplementation in Ultra-trail Runners: a Double-blind Randomized Placebo-controlled Trial","ECUM-RUN","Inclusion Criteria:\n\n* Age ≥ 18 years at inclusion\n* Registered for \"La Diagonale des Fous\" (Grand Raid de La Réunion, 175 km, 2026 edition)\n* Free, informed, signed consent obtained prior to any study-related procedure\n* Availability to participate in the full protocol, including preliminary consultations and biological sampling at all time points (T0 to T3)\n* Affiliated with or beneficiary of a social security scheme\n* Ability to understand and follow study instructions (sufficient French language level, or assistance available)\n\nExclusion Criteria:\n\n* Regular NSAID use in the 30 days prior to inclusion, defined as intake at least 3 days\u002Fweek for at least 2 consecutive weeks, or ongoing treatment at the time of inclusion\n* Regular use of curcumin-containing supplements or \"9-5-1\"-type preparations in the 30 days prior to inclusion, defined as intake at least 3 days\u002Fweek for at least 2 consecutive weeks\n* Taking anticoagulant treatment\n* History of hepatic, biliary, or pancreatic disease, including: gallstones, cholestasis, acute or chronic hepatitis, cirrhosis\n* Known allergy or documented hypersensitivity to any capsule component: turmeric, curcumin, ginger, black pepper, maltodextrin, or hydroxypropylmethylcellulose (HPMC)\n* Chronic inflammatory joint disease (e.g., rheumatoid arthritis, spondyloarthritis) under active specific treatment\n* Pregnancy or breastfeeding\n* Participation in another biomedical study involving a therapeutic intervention within the 30 days prior to inclusion\n* Severe cognitive or psychiatric impairment preventing understanding of the protocol or completion of questionnaires\n* Patient under guardianship\u002Fcuratorship or subject to a legal protection order",true,"ALL","18 Years",{"count":21,"type":22},100,"ESTIMATED","INTERVENTIONAL",[25],"NA","ECUM-RUN is a randomized, double-blind, placebo-controlled phase 3 trial evaluating whether a 30-day oral supplementation with curcumin, ginger, and piperine (9-5-1 formulation) reduces exercise-induced joint pain and inflammatory markers in 82 ultra-trail runners competing in the Diagonale des Fous (175 km). The primary endpoint is the change in knee pain (VAS score) between end of supplementation and race finish, compared between intervention and placebo groups.",[28],"Joint Pains","NOT_YET_RECRUITING","2026-07-08",{"date":32,"type":33},"2026-07-13","ACTUAL",{"date":35,"type":22},"2026-09-14",{"date":37,"type":22},"2026-10-20",{"name":39,"class":40},"Centre Hospitalier Universitaire de la Réunion","OTHER",{"id":42,"slug":43,"hasResults":12,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":12,"sex":18,"minAge":48,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":52,"conditions":53,"keywords":55,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":4},"100644822","the-value-of-a-simple-tool-for-the-early-detection-of-decompensated-heart-failure-in-people-over-55-on-runion-island-a-preliminary-study-in-hospitals-depistic-run-100644822","NCT07673562","The Value of a Simple Tool for the Early Detection of Decompensated Heart Failure in People Over 55 on Réunion Island: A Preliminary Study in Hospitals (DEPIST'IC-RUN)","DEPIST'IC-RUN","Inclusion Criteria:\n\nPatients:\n\n* Aged 55 and older\n* Admitted on an unscheduled basis to the cardiology department at the CHU (North and South campuses) and the CHOR for any reason (in general wards or intensive care)\n* Residents of Réunion\n* Able to read and write French\n* Enrolled in a social security program\n* Willing to participate in the study\n\nExclusion Criteria:\n\nPatients:\n\n* Who cannot communicate in French\n* For whom it is impossible to administer the questionnaire\n* For whom the ETT and\u002For cardiology consultation are impossible\n* Who are under guardianship, conservatorship, or judicial protection","55 Years",{"count":50,"type":22},300,"OBSERVATIONAL","The goal of this study is to assess the discriminatory power of a previously developed tool for detecting decompensated heart failure-which includes, in particular, clinical signs-in a population of patients hospitalized in cardiology units in Réunion. The main question it aims to answer is : Would a simple and rapid screening tool for decompensated heart failure help identify a high probability of this condition in a population hospitalized in a cardiology unit in Réunion? This study includes patients aged 55 and older, who reside in Réunion, who were admitted on an unscheduled basis to the cardiology department at the Réunion University Hospital or the Ouest Réunion Hospital, for any reason (whether as an inpatient or in the intensive care unit)\n\nThe study is conducted in two phases:\n\nPhase 1: Development of the new e-DELPHI consensus-based screening tool Phase 2: Administration of the Déspist'IC-Run early detection tool for decompensated heart failure and performance of the gold standard cardiology examination (RIPH3)",[54],"Heart Failure",[56,57,58],"Decompensated heart failure","early detection","questionnaire","2026-06-23",{"date":61,"type":33},"2026-06-29",{"date":63,"type":22},"2026-08-12",{"date":65,"type":22},"2027-02",{"name":39,"class":40},{"id":68,"slug":69,"hasResults":12,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":75,"targetDuration":4,"studyType":23,"phases":77,"briefSummary":78,"conditions":79,"keywords":81,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":4},"100644554","effects-of-a-qi-gong-program-on-dissociative-symptoms-in-patients-who-have-experienced-childhood-trauma-a-randomized-controlled-trial-qi-t-100644554","NCT07670663","Effects of a Qi Gong Program on Dissociative Symptoms in Patients Who Have Experienced Childhood Trauma: a Randomized Controlled Trial (Qi-T)","Effects of a Qi Gong Program on Dissociative Symptoms in Patients Who Have Experienced Childhood Trauma: a Randomized Controlled Trial","Qi-T","Inclusion Criteria:\n\n* 18 years of age or older\n* A score above the 10th percentile on the Dissociative Experience Scale-II (DES-II)\n* A score above 2 on the ACE scale (Adverse Childhood Experiences by Felitti et al., 1998)\n* A medical certificate attesting to the participant's fitness to practice Qigong\n* A person enrolled in or receiving benefits from a social security program\n* Free, informed, and written consent signed by the participant and the investigator (no later than the day of enrollment and prior to any examination required by the study).\n\nExclusion Criteria:\n\n* In a suicidal crisis\n* In a hallucinatory crisis\n* Experiencing a major depressive episode\n* Unstabilized\n* Pregnant women\n* Those who do not understand French\n* Under guardianship or conservatorship\n* Under judicial protection",{"count":76,"type":22},90,[25],"The goal of this clinical trial is to evaluate whether participation in 12 Qi Gong sessions (intervention group), compared with usual care without Qi Gong (control group), reduces dissociative symptoms, as measured by the Dissociative Experience Scale-II (DES-II), between T0 and T1, in outpatients hospitalized for psychiatric disorders related to aversive experiences during childhood.\n\nThe main questions it aims to answer are:\n\n\\- a) To assess whether participation in the Qi Gong program leads to a reduction in symptoms related to complex trauma, b) To assess whether participation in the Qi Gong program leads to an increase in the level of mindfulness c) To explore whether the effect of the Qi Gong program on reducing dissociative symptoms varies according to participants' baseline level of dissociation (Dissociative Experiences Scale-II ) d) To explore whether the effect of the Qi Gong program on reducing dissociative symptoms is sustained over time e) To explore the experiences of patients who participated in the Qi Gong sessions following the intervention.\n\nThis is a randomized controlled trial with parallel groups:\n\n* Intervention group: participation in 12 Qi Gong sessions led by a trained professional, in addition to standard care\n* Control group: standard care, without access to Qi Gong sessions during the study period.\n\nParticipants will be required to:\n\n* complete 3 questionnaires (DES-II, ITQ, MAAS)\n* attend one Qi Gong session per week for 12 weeks (including a group debriefing) or receive standard care at a medical-psychological center (without Qi Gong)\n* complete the same questionnaires (DES-II, ITQ, MAAS) after the 12 weeks\n* complete the DES-II questionnaire 2 months later",[80],"Psychiatry",[82,83,84],"dissociative symptoms","childhood trauma","Qi- Qong","2026-06-22",{"date":87,"type":33},"2026-06-26",{"date":89,"type":22},"2026-09",{"date":91,"type":22},"2029-03",{"name":39,"class":40},{"id":94,"slug":95,"hasResults":12,"nctId":96,"briefTitle":97,"officialTitle":97,"acronym":98,"eligibilityCriteria":99,"healthyVolunteers":12,"sex":18,"minAge":100,"maxAge":101,"enrollmentInfo":102,"targetDuration":4,"studyType":23,"phases":104,"briefSummary":105,"conditions":106,"keywords":4,"overallStatus":111,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":120},"100607592","against-chikungunya-virus-and-neonatal-infection-100607592","NCT07190560","Against Chikungunya Virus and Neonatal Infection","ConvictionCHIK","Inclusion Criteria:\n\n* Treatment group\n\nNewborn:\n\n* whose mother has a clinical and\u002For laboratory diagnosis of Chikungunya (CHIK) infection occurring between 2 days before and 2 days after birth.\n* Hospitalized in a Level III neonatology unit in Mayotte or at the University Hospital of La Réunion.\n* Eligible for experimental treatment (called PC-CHIK-V):\n\n  * If the maternal infection was diagnosed between2 days before and the day of delivery, treatment can be administered within the first 12 hours of the newborn's life.\n  * If the maternal infection was diagnosed between 1 day and 2 days after birth, treatment can be administered within 12 hours of diagnosis.\n* Whose holders of parental authority have given free, informed, and written consent prior to any examination required for the research. Parallel Cohort of\n\nUntreated Newborns (parallel observational cohort)\n\nNewborns:\n\n* Whose mother has a clinical and\u002For laboratory diagnosis of CHIK-V infection occurring between 2 days before and 2 days after birth.\n* Hospitalized in a Level III neonatology unit in Mayotte or at the University Hospital of La Réunion.\n* Not treated with PC-CHIK-V:\n* Monitored in one of the units of the Neonatology Department for at least 5 days from the day of birth.\n* Whose holders of parental authority (or the holder if the mother is the sole holder of parental authority) have been informed of the research and have not objected to the use of data collected during hospitalization for research purposes.\n\nExclusion Criteria:\n\n* Newborns who present at birth with clinical criteria for ahypoxic-ischemic encephalopathy (HIE) that require therapeutic hypothermia according to the national protocol for \"neonatal therapeutic hypothermia\"\n* Newborns who require phototherapy treatment at the time of enrollment using devices with a maximum energy wavelength less than 425 nm and\u002For with an emission bandwidth with a lower limit of \\\u003C375 nm.","0 Days","2 Days",{"count":103,"type":22},60,[25],"The goal of this clinical trial is to learn if administration of plasma, from a whole blood donation from an individual who has declared a Chikungunya infection for less than 6 months , to a newborn, whose mother has a peripartum chikungunya infection, will have an impact on the proportion of newborns surviving without encephalitis\u002Fencephalopathy (EE) within the first 5 days of life. Researchers will compare results to an observational study of 30 newborns who couldn't have been proposed to participate at the clinical trial, because of delay of diagnosis or delay of transfer to hospital which doesn't allow transfusion or parents not accepting plasma transfusion to the newborn.\n\nParticipants of the clinical trial will:\n\n* receive a transfusion,\n* visit the clinic and undergo biological tests every day until day 7 and once between 1 and 3 months.\n\nParticipant of observational study as part of their regular medical care, and biological data will be reused for the research from the mother's diagnosis until the newborn reaches 3 months of age",[107,108,109,110],"Chikungunya Virus Infection","Neonatal","Transfusion","Encephalopathy","RECRUITING","2026-05-04",{"date":114,"type":33},"2026-05-08",{"date":116,"type":22},"2026-08-01",{"date":118,"type":22},"2027-12-01",{"name":39,"class":40},2,{"id":122,"slug":123,"hasResults":12,"nctId":124,"briefTitle":125,"officialTitle":126,"acronym":127,"eligibilityCriteria":128,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":129,"targetDuration":4,"studyType":23,"phases":130,"briefSummary":131,"conditions":132,"keywords":4,"overallStatus":111,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":120},"100552808","impact-of-sms-reminder-on-weight-loss-as-part-of-a-health-pathway-in-patients-with-prediabetes-prediabcoach-100552808","NCT06477900","Impact of SMS Reminder on Weight Loss, as Part of a Health Pathway in Patients With Prediabetes (PREDIABCOACH)","Impact of SMS Reminder on Weight Loss, as Part of a Hygieno-dietary Health Pathway in Patients With Prediabetes: a Randomized Controlled Trial.","PREDIABCOACH","Inclusion Criteria:\n\n* Subject with prediabetes as defined by HAS (fasting blood glucose \\> 1.10g\u002FL and \\\u003C 1.26g\u002FL; or blood glucose 2h after ingestion of 10g of glucose \\> 1.40g\u002FL and \\\u003C 2g\u002FL \\[HGPO test\\])\n* included in a health and diet care program for patients with pre-diabetes offered by one of Réunion's CPTS (FindRisc Péi-CPTS program)\n* age \\> 18 years\n* in possession of an SMS-enabled telephone\n* able to complete self-efficacy questionnaires\n* not expected to move within 12 months\n\nExclusion Criteria:\n\n* participant currently being monitored in the PREDIABRUN study\n* protected adults (under guardianship or curatorship)\n* pregnant women\n* refusal to participate in the study\n* patients unable to speak Creole or French",{"count":50,"type":22},[25],"The goal of this interventionnal study is to demonstrate that sending SMS messages with advice on physical activity or nutrition, in addition to a program of hygienic-dietary management, significantly increases weight loss in subjects with prediabetes in La Réunion.\n\nIndeed, type 2 diabetes is a priority health problem on Reunion Island: 10% of the population are treated for type 2 diabetes, twice as many as in France.\n\nInternational studies have demonstrated the value of modifying dietary and physical activity habits to reduce the risk of transition to diabetes in patients with prediabetes Against this backdrop, a Regional Nutrition Diabetes Program (PRND) 2020-2023 was launched by Réunion's Regional Health Agency (ARS) in 2020.\n\nStudies have also demonstrated the effectiveness of using SMS to encourage and support weight loss interventions.\n\nSo, the main question it aims to answer are:\n\n• Does the addition of 72 SMS of physical activity and nutriton advice, to the \"FindRisc Péi-CPTS\" program, significantly increase weight loss by 3% after 6 months of starting the program.\n\nFindRiscPei-CPTS program includes sports sessions, dietary consultations and therapeutic education.\n\nThe 300 participants will be randomized into two arms\n\n* 150 participants will take part in the FindRiscPei-CPTS program + receive SMS messages\n* 150 participants will only take part in the FindRiscPei-CPTS program (no SMS)\n\nAll participants will follow procedures below:\n\n* Inclusion: assessment of weight and waist circumference, Lifestyle Questionnaire and Socio-Efficacy Questionnaire.\n* Participation in Findrisk program for 3 to 9 months (+ SMS for experimental group)\n* 3 follow-up visits: 3 months, 6 months and 9 months after starting the program: weight and waist measurement, self-efficacy questionnaire.",[133],"PreDiabetes","2026-03-17",{"date":136,"type":33},"2026-03-19",{"date":138,"type":33},"2025-01-22",{"date":140,"type":22},"2028-11",{"name":39,"class":40},{"id":143,"slug":144,"hasResults":12,"nctId":145,"briefTitle":146,"officialTitle":146,"acronym":147,"eligibilityCriteria":148,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":149,"targetDuration":4,"studyType":23,"phases":151,"briefSummary":152,"conditions":153,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":155,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":4},"100544231","psychotrauma-prevention-algorithm--randomized-controlled-pilot-study-100544231","NCT06366191","Psychotrauma Prevention Algorithm : Randomized, Controlled Pilot Study","A2P","Inclusion Criteria:\n\n* Person who the vital prognosis has or could have been committed or having felt a threat to his physical and\u002For psychological integrity\n* After a potentially traumatic event dating from a minimum of 72 hours to a maximum of 1 week\n* for which the CUMP or the psychotrauma regulation platform has been requested\n* having lived or being a direct witness of the event\n* knowing how to read and write\n* affiliate or beneficiary of a social security scheme\n* having signed a consent\n\nNon-inclusion Criteria:\n\n* guardianship or curatorship\n* unable to receive phone calls\n* unable to go to a place for consultation",{"count":150,"type":22},40,[25],"A randomized pilot study which proposes to patients having suffered a traumatic event to have either only the standard care or the standard care associated with adaptated psychotrauma watch and prevention system.",[154],"Psychological Trauma",{"date":136,"type":33},{"date":157,"type":22},"2026-06",{"date":159,"type":22},"2026-11",{"name":39,"class":40},{"id":162,"slug":163,"hasResults":12,"nctId":164,"briefTitle":165,"officialTitle":166,"acronym":167,"eligibilityCriteria":168,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":169,"enrollmentInfo":170,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":172,"conditions":173,"keywords":177,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":4},"100629950","creation-of-a-scale-for-assessing-pain-and-discomfort-in-extremely-premature-infants-edex-hospitalised-in-neonatal-intensive-care-inspired-by-the-early-infant-pain-and-discomfort-scale-edin-100629950","NCT07481331","Creation of a Scale for Assessing Pain and Discomfort in Extremely Premature Infants (EDEX) Hospitalised in Neonatal Intensive Care, Inspired by the Early Infant Pain and Discomfort Scale (EDIN)","Creation of a Scale for Assessing Pain and Discomfort in Extremely Premature Infants (EDEX) Hospitalised in Neonatal Intensive Care, Inspired by the Early Infant Pain and Distress Scale (EDIN)","DOU-PREMA","Inclusion Criteria:\n\nExtremely premature infants:\n\n* born before 27 weeks of gestation, and aged no more than 26 weeks of amenorrhea + 6 days in corrected age,\n* from 48 hours of life,\n* hospitalised in neonatal intensive care,\n* for whom at least one of the two legal guardians has given their consent.\n\nExclusion Criteria:\n\nExtreme premature infants:\n\n* whose clinical condition is critical with a risk of imminent death,\n* with major brain damage (HIV 4) or major brain malformations,\n* deeply sedated or paralyzed with no spontaneous reactions,\n* whose parents are both minors.\n* who are not already participating in another study.","27 Weeks",{"count":171,"type":22},68,"The goal of this study is to develop a new scale for assessing prolonged pain, dedicated to extremely premature infants born before 27 weeks of gestation, adapted to their particular ways of expressing pain and discomfort, which will be called the EDEX (Extremely Premature Infant Pain Assessment Scale).\n\nThis scale will take into account the level of development of extremely premature infants, recognizing that the perception and manifestations of pain vary according to gestational age.\n\nIt was chosen to develop a specific pain assessment scale for preterm infants born before 27 weeks of gestation, in line with their level of development and their relatively homogeneous manifestations in this population.\n\nThis population, which is the most immature, is particularly fragile and sensitive to its environment and the care provided. Pain manifestations are the most subtle, vegetative reactions are very present, and the motor system is still underdeveloped, linked to low muscle tone.\n\nIt is with this category of patients that the nursing staff encounter the most difficulty in assessing pain and discomfort based on the EDIN scale.\n\nAfter creating the new EDEX scale during the first phase of the DOU-PREMA study, both scales (EDIN and EDEX) will be administered to the same pool of extremely premature infants during the second phase of the DOU-PRÉMA study in order to assess the correlation between the two scales.\n\nThe main hypothesis is that EDIN and EDEX scores will not be correlated, as the EDIN does not appear to be suitable for extremely premature infants in routine practice.\n\nif the hypothesis is confirmed, a multicenter psychometric validation of the EDEX scale will then be considered in a future study.\n\nThe study is a monocentric, non-interventional observational study conducted in the neonatal intensive care unit (NICU) of the University Hospital of Reunion Island (Site Nord). It is designed as a preliminary step toward the psychometric validation of a newly developed behavioral pain and discomfort assessment scale for extremely preterm infants (\\\u003C27 weeks' gestational age), named EDEX.\n\nThe study includes two sequential phases:\n\n1. a developmental phase dedicated to the creation of the EDEX scale : This stage is based on the production of videos of premature extreme in order to ajust the provisional scale define during a multidisciplinary meeting.\n2. a cross-sectional observational phase comparing EDEX with the EDIN scale in the same population.\n\nThe second phase of the project will evaluate the correlation between EDIN and EDEX scores.\n\nThis protocol follows the SPIRIT recommendations for study protocols involving human participants.",[174,175,176],"Extremely Premature Infant","Pain","Discomfort Symptoms",[178,179],"pain and discomfort scale","extremely premature infants","2026-03-16",{"date":182,"type":33},"2026-03-18",{"date":184,"type":22},"2026-04",{"date":186,"type":22},"2028-02",{"name":39,"class":40},{"id":189,"slug":190,"hasResults":12,"nctId":191,"briefTitle":192,"officialTitle":192,"acronym":193,"eligibilityCriteria":194,"healthyVolunteers":17,"sex":18,"minAge":195,"maxAge":196,"enrollmentInfo":197,"targetDuration":4,"studyType":23,"phases":199,"briefSummary":200,"conditions":201,"keywords":204,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":209,"lastUpdatePostDateStruct":210,"startDateStruct":212,"completionDateStruct":213,"leadSponsor":215,"locationsCount":216},"100612289","adaptation-of-the-mini-mental-state-examination-mmse-for-the-reunion-island-population-100612289","NCT07251647","Adaptation of the Mini-Mental State Examination (MMSE) for the Reunion Island Population","MMSE-RUN","Inclusion criteria:\n\n* For the healthy population : aged 60 to 89 years, residing in Reunion for more than 5 years, able to understand the test instructions, available for a one-hour interview, affiliated with a social security scheme, with informed consent.\n* For the sick population : aged 60 to 89 years, residing in Reunion for more than 5 years, presenting probable or possible Alzheimer's disease and\u002For probable vascular cognitive disorder, able to understand the test instructions, available for a one-hour interview, affiliated with a social security scheme, with informed consent.\n\nExclusion criteria:\n\n* For the healthy populationhistory of neurological pathology, neurodegenerative pathology with cognitive expression, refusing to participate in the study, under legal protection.\n* For the sick population: acute unresolved medical decompensation or acute psychic decompensation, refusing to participate in the study, under legal protection.","60 Years","89 Years",{"count":198,"type":22},400,[25],"The Mini-Mental State Examination (MMSE) is the most widely used cognitive screening and monitoring test for neurocognitive disorders in current clinical practice. Its French version was published in 1998 by the GRECO group (MMSE-GRECO). However, some items of this French version are not adapted to local Reunionese particularities.\n\nThe main objective is to propose and validate the psychometric properties of an adapted version of the MMSE, to the Reunionese culture (MMSE-RUN) in a healthy population and in a sick population (Alzheimer's Disease and Vascular Cognitive Disorder), and to compare its performance with the MMSE-GRECO.",[202,203],"Alzheimer s Disease","Vascular Cognitive Impairment",[205,206,207,208],"Neurocognitive disorder","cognitive test","screening","Reunion Island","2026-03-11",{"date":211,"type":33},"2026-03-12",{"date":184,"type":22},{"date":214,"type":22},"2027-07",{"name":39,"class":40},7,{"id":218,"slug":219,"hasResults":12,"nctId":220,"briefTitle":221,"officialTitle":222,"acronym":223,"eligibilityCriteria":224,"healthyVolunteers":12,"sex":18,"minAge":225,"maxAge":19,"enrollmentInfo":226,"targetDuration":4,"studyType":23,"phases":228,"briefSummary":229,"conditions":230,"keywords":4,"overallStatus":111,"whyStopped":4,"lastUpdateSubmitDate":209,"lastUpdatePostDateStruct":232,"startDateStruct":234,"completionDateStruct":236,"leadSponsor":238,"locationsCount":239},"100484751","use-of-virtual-reality-in-pain-management-in-pediatric-oncology-100484751","NCT05592132","Use of Virtual Reality in Pain Management in Pediatric Oncology","Use of Virtual Reality in Pain Management During Invasive Gestures in Pediatric Oncology: Randomized Controlled Trial","DOREVI","Inclusion Criteria:\n\n* patient who tolerates the virtual reality headset\n* patient followed in pediatric oncology\n* patient with a diagnosis of benign tumor or cancer\n* patient who needs to have painful medical procedure during their treatment\n* patient whose parents have signed the informed consent\n* patient affiliated with social security or equivalent\n\nExclusion Criteria:\n\n* patient with visual or hearing impairement\n* patient with epilepsy or other neurological disease\n* patient with psychiatric disease","6 Years",{"count":227,"type":22},74,[25],"DOREVI is a monocentric randomized controlled study that will evaluate the efficacy of virtual reality helmets for pain prevention during invasive care on 78 oncologic pediatric patients. Two groups of children (between 6 and 11 and between 12 and 18 years old) will be randomized to use helmet plus standard care or standard care alone during invasive procedures (central venous catheter puncture, lumbar puncture, or bone marrow aspiration). The pain intensity will be evaluated using a visual analogic scale during three invasive procedures, and results will be compared between the patients with or without virtual reality.",[231],"Pediatric Tumor",{"date":233,"type":33},"2026-03-13",{"date":235,"type":33},"2023-01-17",{"date":237,"type":22},"2026-05",{"name":39,"class":40},1,{"id":241,"slug":242,"hasResults":12,"nctId":243,"briefTitle":244,"officialTitle":244,"acronym":245,"eligibilityCriteria":246,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":247,"targetDuration":4,"studyType":23,"phases":249,"briefSummary":250,"conditions":251,"keywords":4,"overallStatus":111,"whyStopped":4,"lastUpdateSubmitDate":209,"lastUpdatePostDateStruct":253,"startDateStruct":254,"completionDateStruct":256,"leadSponsor":258,"locationsCount":239},"100416366","interest-of-cardiac-coherence-in-the-prevention-of-chronic-post-traumatic-stress-disorder-pilot-study-100416366","NCT04701723","Interest of Cardiac Coherence in the Prevention of Chronic Post-traumatic Stress Disorder: Pilot Study","COHEPS-P","Inclusion Criteria:\n\n* patients seen at medico-psychological emergency cell\n* patients with an acute stress disorder, diagnosed by DSM-5\n* patients who have experienced a potentially traumatic event for the last 3-15 days (vctim or witness)\n* patients able to read and write in French language\n* person affiliated or beneficiary of a social security scheme.\n* person who agrees to participate in the study\n\nExclusion Criteria:\n\n* patients with respiratory pathology not allowing cardiac coherence training\n* patients currently practicing a regular respiratory control technique or within the last 6 months\n* patients taking beta-blocker, betamimetic, anti-arrhythmic, opioid, antidepressant\n* patients with a pacemaker or suffering from severe cardiac illness\n* patients with non-stabilized psychiatric disorder at inclusion\n* patient taking benzodiazepine unable to wean off in the week following the inclusion\n* patients with addiction\n* patients with a cognitive deficit\n* patients under guardianship or curatorship, under judicial supervision",{"count":248,"type":22},44,[25],"ThThe aim of this study is to determinate the potential benefits of a respiratory training program (cardiac coherence, CC) in patients suffering from acute stress disorder, after a potentially traumatic event. Using this method is supposed to prevent the onset of chronic post traumatic stress disorder after 3 months.\n\nThis pilot study will help to determinate the need of developing this kind of complementary and alternative program, and will also provide knowledge about the feasibiility and acceptability of this program for the patients.",[252],"Post-traumatic Stress Disorder",{"date":211,"type":33},{"date":255,"type":33},"2021-07-19",{"date":257,"type":22},"2027-05",{"name":39,"class":40},{"id":260,"slug":261,"hasResults":12,"nctId":262,"briefTitle":263,"officialTitle":263,"acronym":264,"eligibilityCriteria":265,"healthyVolunteers":12,"sex":266,"minAge":267,"maxAge":268,"enrollmentInfo":269,"targetDuration":4,"studyType":23,"phases":270,"briefSummary":271,"conditions":272,"keywords":4,"overallStatus":111,"whyStopped":4,"lastUpdateSubmitDate":274,"lastUpdatePostDateStruct":275,"startDateStruct":277,"completionDateStruct":279,"leadSponsor":281,"locationsCount":120},"100626626","concordance-and-acceptability-of-self-screening-compared-to-screening-carried-out-by-a-health-professional-for-hpv-a-risk-factor-for-anal-cancer-by-swab-in-people-living-with-hiv-a-randomized-controlled-crossover-study-100626626","NCT07438080","Concordance and Acceptability of Self-screening Compared to Screening Carried Out by a Health Professional for HPV, a Risk Factor for Anal Cancer, by Swab in People Living With HIV. A Randomized Controlled Crossover Study","ALONDEPISTHPV","Inclusion Criteria:\n\n* Aged 30 to 65,\n* In a vulnerable situation (beneficiary of a state or departmental social service, or referred by a charity),\n* Resident in one of the two municipalities targeted by the study,\n* Supported by the social services of one of the two municipalities targeted by the study,\n* Having agreed to participate in sexual health awareness meetings organized on site\n\nExclusion Criteria:\n\n* Refusing to participate in the study\n* Having had a hysterectomy","FEMALE","30 Years","65 Years",{"count":50,"type":22},[25],"Comunity health actions are set up in populations of women aged 30 to 65 in vulnerable situations living in the outlying areas of Reunion Island.\n\nThe idea is to evaluate those action on health",[273],"HPV","2026-02-26",{"date":276,"type":33},"2026-02-27",{"date":278,"type":33},"2025-04-09",{"date":280,"type":22},"2028-03-01",{"name":39,"class":40},{"id":283,"slug":284,"hasResults":12,"nctId":285,"briefTitle":286,"officialTitle":286,"acronym":287,"eligibilityCriteria":288,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":289,"targetDuration":4,"studyType":23,"phases":290,"briefSummary":291,"conditions":292,"keywords":295,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":274,"lastUpdatePostDateStruct":297,"startDateStruct":299,"completionDateStruct":301,"leadSponsor":303,"locationsCount":239},"100627121","prospective-analysis-of-self-medication-with-phytotherapy-in-nephropatic-patients-100627121","NCT07444515","Prospective AnalysiS of Self medIcation With phytOtherapy in Nephropatic Patients.","PASSION","Inclusion Criteria:\n\nIndividual:\n\n* Adult\n* Resident of Réunion Island and planning to remain on the island for the year following enrollment\n* Chronic Kidney Disease Stage 3, 4, or 5, not on dialysis\n* Under the care of a nephrologist\n* Able to complete a questionnaire\n* Registered with social security\n\nExclusion Criteria:\n\nIndividual:\n\n* Kidney transplant recipient\n* Adult under guardianship or legal protection\n* Pregnant or breastfeeding women, or women planning a pregnancy during the enrollment period",{"count":198,"type":22},[25],"We propose the following hypotheses:\n\n* The use of herbal medicine is common among patients with chronic kidney disease in Réunion island.\n* This use could influence the progression of kidney disease in these patients. To assess the primary inclusion criterion, patients will be easily identified by nephrologists through existing follow-up. The questionnaires will be administered after this early identification by the investigators at each center.\n\nThe primary evaluation criterion is straightforward: it aims to establish an overview of the use of herbal medicine in our patient population. This information is currently unavailable and remains crucial for measuring the extent of the issue. Our secondary criteria will involve more in-depth analysis of this use and an attempt to correlate the use of certain herbs with the rate of progression of kidney disease at one year.\n\nWe targeted patients with moderate to end-stage chronic kidney disease (KDIGO classification 3 to 5), which are the stages typically included in kidney disease studies. Furthermore, these patients are the most likely to experience a greater annual progression of their kidney disease, and the effect of herbs on this progression could be investigated. Transplant patients were not included because they are more aware of the risks of not using herbal medicine due to their use of immunosuppressants.",[293,294],"Chronic Kidney Disease (Stage 3-4)","Chronic Kidney Disease (Stages 4 and 5)",[296],"phytotherapy",{"date":298,"type":33},"2026-03-03",{"date":300,"type":22},"2026-04-02",{"date":302,"type":22},"2028-07-02",{"name":39,"class":40},{"id":305,"slug":306,"hasResults":12,"nctId":307,"briefTitle":308,"officialTitle":309,"acronym":310,"eligibilityCriteria":311,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":312,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":314,"conditions":315,"keywords":317,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":325,"lastUpdatePostDateStruct":326,"startDateStruct":328,"completionDateStruct":330,"leadSponsor":332,"locationsCount":239},"100626110","validation-of-the-shared-happiness-index-in-multidisciplinary-primary-care-practices--be-api--100626110","NCT07431372","Validation of the Shared Happiness Index in Multidisciplinary Primary Care Practices ( Be aPi )","Validation of the Shared Happiness Index in Multidisciplinary Primary Care Practices","Be aPi","Inclusion Criteria:\n\n* Healthcare professionals (medical, paramedical) and professionals in the medical-social sector, medical assistants, health coordinators and mediators, as well as adapted physical activity instructors and psychologists\n* who work in healthcare centres that had been operating for more than one year at the start of the study and who themselves had more than one year's seniority in the MSP.\n\nExclusion Criteria:\n\n* Substitute professionals,\n* Secretaries without coordination or medical assistant duties Professionals belonging to MSPs that had been operating for less than one year at the start of the study and who had less than one year's seniority within the organisation.",{"count":313,"type":22},350,"Multi-professional primary care practices (Maisons de Santé Pluriprofessionnelles, MSP) have expanded widely in France over the last decade to respond to increasing healthcare needs, uneven distribution of physicians, and deteriorating working conditions, which were further exacerbated by the COVID-19 pandemic. MSPs are expected to offer more collaborative and coordinated care, and to provide a more attractive work environment, particularly for younger healthcare professionals seeking less isolation and better work-life balance.\n\nWell-being at work for healthcare professionals is now recognised as a key determinant of quality and safety of care. Studies have shown links between staff satisfaction, burnout, and patient outcomes, including communication quality, error rates and staff retention. However, research specifically focused on collective well-being or \"shared happiness\" within multi-professional primary care teams remains limited. Existing work in French MSPs (notably qualitative studies by F. Burté and O. Caillaud) has identified relevant dimensions of \"shared happiness\" and led to the preliminary construction of a questionnaire named the Shared Happiness Index (Indice de Bonheur Partagé, IBP). To date, no validated, standardised instrument exists to measure this collective well-being in MSPs.\n\nThe Be\\_aPi study aims to validate the IBP questionnaire among healthcare professionals working in MSPs. The study is observational, descriptive and cross-sectional, conducted in several French regions covered by the GIRCI (Groupement Interrégional de Recherche Clinique et Innovation) SOHO (Sud-Ouest Outre-Mer Hospitalier) network (Nouvelle-Aquitaine, Occitanie, Réunion and Mayotte). It comprises three main steps. First, a content validation phase will be carried out with two independent panels of experts. One panel, including psychometrics, methodology and linguistics experts and MSP representatives, will assess face validity by examining each item in relation to the concept of shared happiness in multi-professional primary care. A second panel will be involved in an e-Delphi process to establish consensus validity on the relevance and clarity of items, using Likert-type ratings and iterative feedback.\n\nSecond, the psychometric validation phase will recruit approximately 350 professionals from over 100 MSPs. Eligible participants include medical and paramedical professionals, medical-social staff, medical assistants, coordinators, health mediators, adapted physical activity instructors and psychologists, working in MSPs that have been operating for at least one year, with at least one year of seniority in their current MSP. Participants will complete an online survey including the IBP questionnaire and three reference instruments: the Maslach Burnout Inventory (MBI), the General Health Questionnaire-12 (GHQ-12) and the Short Form-12 (SF-12). Internal consistency of the IBP will be assessed using Cronbach's alpha, and construct validity will be examined with exploratory factor analysis and correlation patterns with the reference scales, according to a multi-trait multi-method approach.\n\nThird, to evaluate test-retest reliability, participants who completed the initial IBP will be invited to fill in the same questionnaire again after a delay of approximately one month. The stability of scores over time will be assessed using intraclass correlation coefficients. Ceiling and floor effects, as well as the distribution of scores across professional categories and organisational characteristics of MSPs (e.g. single-site vs multi-site, role in the organisation, membership in interprofessional associations), will also be analysed.\n\nThe expected outcome of Be\\_aPi is a valid, reliable and transferable Shared Happiness Index specifically tailored to multi-professional primary care practices. This tool should enable regular monitoring of collective well-being, support targeted quality-of-work-life interventions, and ultimately contribute to improving quality and safety of care, staff retention and the long-term sustainability of MSPs. In the longer term, the IBP could inform policy instruments and financing schemes that aim to \"take care of those who care,\" in line with national quality and safety strategies.",[316],"Well Being",[318,319,320,321,322,323,324],"shared hapiness","Primary care","Multidisciplinary primary care practices","Work-related well-being","Quality of work life","Burnout","Shared happiness","2026-02-23",{"date":327,"type":33},"2026-02-24",{"date":329,"type":22},"2026-03",{"date":331,"type":22},"2027-09",{"name":39,"class":40},{"id":334,"slug":335,"hasResults":12,"nctId":336,"briefTitle":337,"officialTitle":337,"acronym":338,"eligibilityCriteria":339,"healthyVolunteers":12,"sex":18,"minAge":340,"maxAge":341,"enrollmentInfo":342,"targetDuration":4,"studyType":23,"phases":344,"briefSummary":345,"conditions":346,"keywords":350,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":358,"lastUpdatePostDateStruct":359,"startDateStruct":361,"completionDateStruct":363,"leadSponsor":365,"locationsCount":4},"100621057","comparison-of-the-best-method-for-measuring-anti-xa-activity-in-children-receiving-unfractionated-heparin-in-cardiac-intensive-care-compaxe-hnf-100621057","NCT07365670","Comparison of the Best Method for Measuring Anti-Xa Activity in Children Receiving Unfractionated Heparin in Cardiac Intensive Care (COMPAXE-HNF)","COMPAXE-HNF","Inclusion Criteria:\n\n* Minors aged 0 to 17 inclusive\n* Weight greater than or equal to 3.5 kg\n* Admitted to resuscitation or congenital cardiac intensive care\n* Requiring treatment with unfractionated heparin at curative doses administered via central venous access\n* Equipped with a central arterial and venous catheter\n* Affiliated with or beneficiary of a social security scheme\n* Free, informed, and written consent signed by one of the two representatives of parental authority and the investigator (no later than the day of inclusion and before any examination required by the research).\n\nExclusion Criteria:\n\n* Newborns \\\u003C 37 weeks gestation\n* Patients treated by a humanitarian organization","1 Day","17 Years",{"count":343,"type":22},22,[25],"This study aims to compare the accuracy of two different blood sampling methods from a central venous catheter (CVC) for measuring anti-Xa activity in children receiving unfractionated heparin (UFH) from this CVC. The results will be compared to a \"gold standard\" sample taken from an arterial catheter (KTA) whithout UFH. The objective is to identify a more reliable method for monitoring UFH, thereby reducing the risk of bleeding or thrombosis in these patients.",[347,348,349],"Congenital Heart Disease","Unfractionated Heparin","Anti Xa Activity",[348,351,352,347,353,354,355,356,357],"Anti-Xa activity","Pediatric Intensive Care","Blood Sampling","Central Venous Catheter","Arterial Catheter","Thrombosis","Hemostasis.","2026-01-16",{"date":360,"type":33},"2026-01-26",{"date":362,"type":22},"2026-04-01",{"date":364,"type":22},"2029-04-05",{"name":39,"class":40},{"id":367,"slug":368,"hasResults":12,"nctId":369,"briefTitle":370,"officialTitle":371,"acronym":372,"eligibilityCriteria":373,"healthyVolunteers":12,"sex":18,"minAge":374,"maxAge":341,"enrollmentInfo":375,"targetDuration":4,"studyType":23,"phases":377,"briefSummary":378,"conditions":379,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":358,"lastUpdatePostDateStruct":382,"startDateStruct":384,"completionDateStruct":386,"leadSponsor":388,"locationsCount":4},"100569670","impact-of-a-telemonitoring-device-on-the-occurever-at-home-in-children-at-risk-of-chemotherapy-induced-neutropenia-100569670","NCT06697262","Impact of a Telemonitoring Device on the Occurever at Home in Children at Risk of Chemotherapy-Induced Neutropenia","Impact of a Telemonitoring Device on the Occurrence of Fever at Home in Children at Risk of Chemotherapy-Induced Neutropenia: A Pilot Randomized Controlled Trial","TELEDOM","Inclusion Criteria:\n\npatient\n\n* Aged 0 to 17 inclusive\n* Followed in the Pediatric Onco-Hematology Department\n* Primo-diagnosed with solid or hematological cancer (incident case)\n* Having received a first cycle of chemotherapy\n* Whose family has psycho-social vulnerabilities assessed by the Froger et al. tool, indicating a need for an IDE to support the family in monitoring the patient.\n\nExclusion Criteria:\n\nPatient:\n\n* with a dermatosis contraindicating the use of the device\n* Refusing to participate in the study","0 Years",{"count":376,"type":22},30,[25],"The goal of this clinical trial is to evaluate the feasibility of the study, measured by the acceptability rate of patients to be recruited in a study proposing temperature monitoring at home, by a remote monitoring device or by the visit of an IDE at home (in association with the usual educational sessions), to children at risk of febrile neutropenia, from families with psycho-social vulnerabilities.\n\nThe main questions it aims to answer are:\n\n* Will participants adhere to the telemonitoring system?\n* Is the intervention feasible, in terms of the device's failure to record temperature data?\n* Will parents behave appropriately when using the device?\n* How satisfied will parents and caregivers be?\n* What will be the physical tolerance of the device?\n* On an exploratory basis, will the remote monitoring system be effective for months?\n\nResearchers will compare :\n\n* patients using the telemonitoring device for continuous temperature monitoring at home, in combination with education sessions on temperature monitoring and the device\n* with patient with temperature monitoring at home by a nurse, 2 times a day, in combination with education sessions on temperature monitoring (without the telemonitoring device at home)",[380,381],"Oncopediatrics","Febrile Neutropenia",{"date":383,"type":33},"2026-01-20",{"date":385,"type":22},"2026-05-01",{"date":387,"type":22},"2028-05-04",{"name":39,"class":40},{"id":390,"slug":391,"hasResults":12,"nctId":392,"briefTitle":393,"officialTitle":394,"acronym":395,"eligibilityCriteria":396,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":397,"targetDuration":4,"studyType":23,"phases":399,"briefSummary":400,"conditions":401,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":358,"lastUpdatePostDateStruct":404,"startDateStruct":405,"completionDateStruct":407,"leadSponsor":409,"locationsCount":239},"100553378","interest-of-a-teteleconsultation-of-a-psychological-support-nurse-on-psychological-distress-in-patients-with-a-primary-malignancy-of-the-central-nervous-system-100553378","NCT06485310","Interest of a TEteleconsultation of a Psychological Support Nurse on Psychological Distress in Patients With a Primary Malignancy of the Central Nervous System","Interest of a TEteleconsultation of a Psychological Support Nurse on Psychological Distress in Patients With a Primary Malignancy of the Central Nervous System Between the Announcement of the Diagnosis and the First Treatment","TECAP","Inclusion Criteria:\n\n* aged 18 and over\n* being treated for a primary malignant tumor of the central nervous system (positive biopsy)\n* with a Mini-Mental State score greater than 24\n* not receiving first-line treatment (chemotherapy, targeted radiotherapy, surgery)\n* with a distress score above 3 on the Psychological Distress Thermometer\n* have access to computer equipment equipped with a microphone and webcam (smartphone, computer)\n* able to read, write and speak French\n* have given free and informed consent\n* being affiliated to a social security scheme\n\nExclusion Criteria:\n\n* with a history of psychiatric illness\n* with recurrent cancer of the cerebral nervous system\n* having begun first-line treatment (drug therapy, curative surgery, radiotherapy or palliative care)\n* under guardianship, curatorship or deprived of liberty",{"count":398,"type":22},58,[25],"The goal of this clinal trial is to compare the effectiveness of nurse-led teleconsultation with usual care (intervention group) on psychological distress in patients with primary malignant tumors of the central nervous system between diagnosis and first anti-cancer treatment, versus usual care alone (control group).\n\nParticipants will be randomized into two groups :\n\n* group A) intervention: usual care + nurse teleconsultation for psychological support\n* group B) control: usual care alone\n\nEnrolment = Day0 (D0)\n\nParticipants will :\n\n* groups A and B: D0: complete 4 questionnaires (Quality of Life, Screening for Distress, Screening for Anxiety and Depression, Social Support Questionnaire)\n* Group A : D0+2\u002F4 das : nursing teleconsultation for psychological support\n* Groups A and B: D0+10days : telephone call to complete the same 4 questionnaires as at inclusion\n* Group A : D0+15days: semi-directive interview, at home, for voluntary patients.",[402,403],"Central Nervous System Cancer","Psychological Distress",{"date":383,"type":33},{"date":406,"type":22},"2026-03-31",{"date":408,"type":22},"2028-06-30",{"name":39,"class":40},{"id":411,"slug":412,"hasResults":12,"nctId":413,"briefTitle":414,"officialTitle":414,"acronym":415,"eligibilityCriteria":416,"healthyVolunteers":12,"sex":18,"minAge":267,"maxAge":4,"enrollmentInfo":417,"targetDuration":4,"studyType":23,"phases":419,"briefSummary":420,"conditions":421,"keywords":423,"overallStatus":111,"whyStopped":4,"lastUpdateSubmitDate":426,"lastUpdatePostDateStruct":427,"startDateStruct":429,"completionDateStruct":431,"leadSponsor":433,"locationsCount":120},"100555117","concordance-and-acceptability-of-self-screening-versus-screening-by-a-healthcare-professional-for-hpv-a-risk-factor-for-anal-cancer-by-swab-in-people-living-with-hiv-100555117","NCT06507917","Concordance and Acceptability of Self-screening Versus Screening by a Healthcare Professional for HPV, a Risk Factor for Anal Cancer, by Swab in People Living With HIV","a-HPVVIH","Inclusion Criteria:\n\nPatient :\n\n* living with HIV\n* aged 30 or over\n* resident on Reunion island and followed at the University Hospital of Reunion Island (the only follow-up center on the island)\n* Able to perform anal self-sampling\n* Able to answer a questionnaire\n* Affiliated with or benefiting from a social security scheme\n* Have given free, informed and signed consent\n\nExclusion Criteria:\n\n* People with a previous anal swab less than 7 days old\n* Persons with a known current diagnosis of anal cancer\n* Persons deprived of liberty by judicial or administrative decision, minors, and persons under legal protection: guardianship or curators",{"count":418,"type":22},398,[25],"Anal canal cancers are on the increase in France, with around 2,000 new cases per year. These lesions can be detected by directed biopsies or smear tests.\n\nThe incidence rate of anal cancer is 30 times higher in people living with HIV than in the general population.\n\nAccording to a recent study, the risk of anal cancer is highest in this population, but is also high in heterosexual men over 30 and women over 30. However, the proposal of a proctological examination in this population is not systematic.\n\nIn France, there is no HPV screening for people living with HIV, but there is a recommendation for proctology consultation in certain cases, notably for men who have sex with men (MSM) or for women with vaginal cervical lesions.\n\nSeveral oncogenic HPV serotypes have been identified in the genesis of anal cancer. The serotype identified as the most carcinogenic is HPV-16 (89%).\n\nThis study will look at anal HPV screening in people over 30 living with HIV, thus including a population for which no screening is currently offered (heterosexual men living with HIV and women living with HIV without vaginal cervical lesions), and will assess the concordance and acceptability of self-screening versus screening by a healthcare professional as part of a comprehensive anal cancer screening strategy in this population.",[422],"HPV Infection",[273,424,425],"HIV","anal screening","2025-12-04",{"date":428,"type":33},"2025-12-11",{"date":430,"type":33},"2025-11-28",{"date":432,"type":22},"2027-01-02",{"name":39,"class":40},{"id":435,"slug":436,"hasResults":12,"nctId":437,"briefTitle":438,"officialTitle":439,"acronym":440,"eligibilityCriteria":441,"healthyVolunteers":12,"sex":18,"minAge":442,"maxAge":341,"enrollmentInfo":443,"targetDuration":4,"studyType":23,"phases":445,"briefSummary":446,"conditions":447,"keywords":4,"overallStatus":111,"whyStopped":4,"lastUpdateSubmitDate":449,"lastUpdatePostDateStruct":450,"startDateStruct":452,"completionDateStruct":454,"leadSponsor":456,"locationsCount":239},"100486228","hypnosis-in-the-management-of-atopic-dermatitis-in-children-and-teenagers-100486228","NCT05611346","HYPNOsis in the Management of Atopic Dermatitis in Children and Teenagers","HYPNOsis in the Management of Atopic Dermatitis in Children and Teenagers : Study Protocol of a Pilot Randomized and Controlled Trial","HypnoDA","Inclusion Criteria:\n\n* Children aged 8 to 17 years\n* Understanding french\n* Have a clinical diagnosis of mild-to-severe AD with a SCORing Atopic Dermatitis (SCORAD)\n* Referred by their referring physician in the Reunionese therapeutic education program for AD provided within the atopy school of the Reunion University Hospital. - Oral consent of the child and of one of the legal representatives collected.\n\nExclusion Criteria:\n\n* Children refusing to participate in the hypnosis session\n* Not having the possibility to listen to an audio file,\n* Already practicing self-hypnosis for their AD before inclusion,\n* Having a contraindication to hypnosis (psychiatric disorders, psychosis)\n* Treated by a systemic treatment for their AD.","8 Years",{"count":444,"type":22},32,[25],"Atopic dermatitis (AD) is a chronic inflammatory dermatosis, common in children. It causes pruritus and skin lesions that can have a significant impact on patients' quality of life. AD can be difficult to treat because of its chronicity, demanding local care, corticophobia and the financial cost of non-reimbursed products. Patients are often looking for therapeutic alternatives. Medical hypnosis is a therapeutic alternative via hypnoanalgesia induced by direct suggestions of comfort and skin soothing and via anxiolysis, by working on stress management and self-esteem reinforcement. Four studies are interested in its action in AD and seem to show a reduction in pruritus, skin pain, an improvement in the intensity of atopic dermatitis, sleep, mood and for some a cure of AD. These results are encouraging but limited by the absence of a control group or by the small population included. Therefore, we propose in a first step to evaluate the feasibility of an hypnosis program through a pilot study, designed in the miniature format of a future, larger scale, randomized controlled trial.",[448],"Dermatitis","2025-09-08",{"date":451,"type":33},"2025-09-12",{"date":453,"type":33},"2024-08-13",{"date":455,"type":22},"2027-12",{"name":39,"class":40},{"id":458,"slug":459,"hasResults":12,"nctId":460,"briefTitle":461,"officialTitle":461,"acronym":462,"eligibilityCriteria":463,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":464,"targetDuration":4,"studyType":23,"phases":466,"briefSummary":467,"conditions":468,"keywords":4,"overallStatus":111,"whyStopped":4,"lastUpdateSubmitDate":470,"lastUpdatePostDateStruct":471,"startDateStruct":473,"completionDateStruct":475,"leadSponsor":477,"locationsCount":239},"100602098","factors-associated-with-hospitalization-and-severity-of-arbovirosis-in-the-indian-ocean-100602098","NCT07119086","Factors Associated With Hospitalization and Severity of Arbovirosis in the Indian Ocean","ARB-OI","1st case :\n\nInclusion Criteria:\n\n* Adult, child or newborn \\> 2.5kg on day of inclusion.\n* Use of one of the hospital departments participating in the research, in an emergency room, full hospitalization, day hospitalization or outpatient clinic.\n* Suspected, probable or biologically confirmed arbovirosis:\n\nA suspected case of arbovirosis is defined as :\n\n* asymptomatic contact case of a patient with probable or confirmed arbovirosis\n* symptomatic or non-symptomatic newborns of mothers who were viremic for arbovirosis during pregnancy, or who had probable or confirmed arbovirosis during pregnancy.\n* In a patient with a history of a stay in an arbovirus circulation zone in the 2 weeks prior to consultation (for imported cases only).\n* In a patient with compatible clinical symptoms during the epidemic period\n\nA probable case of arbovirosis is defined by :\n\n* the association of at least 2 objectified or reported signs or biology suggestive of arbovirosis: fever (reported by the patient or family, or documented), headache, rash, myalgias, arthralgias, abdominal pain, bleeding, thrombocytopenia, or\n* for children under 6: by the reporting (by the family or documented) of a fever on the day of inclusion or in the preceding 7 days, possibly accompanied by pain.\n\nA biologically confirmed case of arbovirosis is defined by :\n\n\\- A positive plasma RT-PCR or urine RT-PCR (Zika virus)\n\nCase 2 : - Retrospectively, patients with sufficiently documented definite, probable or suspected arbovirosis, who give oral consent for their data to be collected retrospectively and\u002For to continue the study follow-up.\n\nExclusion Criteria:\n\n1\\. Patient ou titulaire de l'autorité parentale non affiliés ou non bénéficiaires d'un régime de sécurité sociale.",{"count":465,"type":22},200,[25],"Arboviroses, such as dengue, chikungunya and the Zika virus, represent a growing threat to public health in the Indian Ocean, but also in Europe and the rest of the world. Réunion has experienced several major epidemics, notably chikungunya in 2005-2006 and dengue since 2018, with a current resurgence of chikungunya. Mayotte was hit by a dengue epidemic in 2019, followed by a few cases of Rift Valley fever. The development of Zika could also affect this region.\n\nArboviruses, transmitted by hematophagous arthropods, require the coexistence of a reservoir and a vector. Dengue fever, transmitted by Aedes mosquitoes, is caused by four serotypes of dengue virus (DENV) from the orthoflavivirus family. Primary infection with one serotype confers lasting specific immunity, but only transient protection against the other serotypes. Chikungunya, caused by an alphavirus, now causes epidemics in major tropical areas. It is also transmitted by Aedes mosquitoes.\n\nArboviruses present four main clinical forms: algoeruptive, hemorrhagic, neurological and arthritic. Dengue fever is 75% asymptomatic, but can progress to a severe form, dengue hemorrhagic fever, characterized by increased vascular permeability and potentially fatal complications. Chikungunya causes a sudden onset of fever, polyarthralgia and maculopapular rash, with possible complications in newborns, the elderly and pregnant women.\n\nUnderstanding the factors associated with hospitalization and the severity of these infections is crucial to improving patient management and optimizing medical resources. This cohort study aims to identify the clinical, demographic and environmental determinants influencing the severity of arbovirosis. By analyzing data from patients who have used a healthcare facility, we hope to establish risk profiles and severity criteria that may or may not be specific to each infection. The results will enable us to better understand the pathophysiology of these viruses, develop targeted prevention strategies and improve treatment protocols, thereby helping to reduce the morbidity and mortality associated with arboviroses in this region.\n\nDue to the current chikungunya epidemic in La Réunion, this study will focus on the inclusion of patients affected by this arbovirosis as early as 2025. Its openness over the coming years will allow sufficient reactivity to include any arbovirosis on the territories of Mayotte and La Réunion.",[469],"Arbovirus Disease","2025-08-11",{"date":472,"type":33},"2025-08-12",{"date":474,"type":33},"2025-06-02",{"date":476,"type":22},"2037-05-05",{"name":39,"class":40},{"id":479,"slug":480,"hasResults":12,"nctId":481,"briefTitle":482,"officialTitle":482,"acronym":483,"eligibilityCriteria":484,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":485,"targetDuration":4,"studyType":23,"phases":487,"briefSummary":489,"conditions":490,"keywords":491,"overallStatus":111,"whyStopped":4,"lastUpdateSubmitDate":493,"lastUpdatePostDateStruct":494,"startDateStruct":496,"completionDateStruct":498,"leadSponsor":500,"locationsCount":239},"100587466","phase-4-real-world-effectiveness-safety-and-immunogenicity-of-chikungunya-vaccination-in-populations-at-risk-of-severe-or-complicated-forms-prospective-study-in-la-runion-100587466","NCT06928753","Real-world Effectiveness, Safety and Immunogenicity of Chikungunya Vaccination in Populations at Risk of Severe or Complicated Forms: Prospective Study in La Réunion","CHIK-RE-VAC","Inclusion Criteria:\n\n* Eligible for anti-chikungunya vaccination according to french Health Authority (HAS)\n* Beneficiary of social security coverage\n* Signature of informed consent form\n\nExclusion Criteria:\n\n* Pregnant women\n* Vaccine contraindication for patients undergoing medical treatment\n* Persons under guardianship, curatorship or safeguard of justice\n* Anyone who has received immunoglobulin or a blood or plasma transfusion 3 months prior to vaccine administration",{"count":486,"type":22},1800,[488],"PHASE4","Against the backdrop of a growing chikungunya epidemic in La Réunion, this prospective study will assess the real-life efficacy, safety and immunogenicity of IXCHIQ® vaccine in vulnerable individuals (seniors, comorbid patients), defined by the French Health Autority (HAS) as at risk of severe or complicated forms and\u002For chronic disabling forms (chronic arthritis, chronic fatigue phenotypes). This study will also provide input for the preparation of a cluster randomized trial on a population scale.",[107],[492],"Prophylaxis, Safety, Efficacy, Vaccine effectiveness, Chikungunya","2025-07-28",{"date":495,"type":33},"2025-07-29",{"date":497,"type":33},"2025-04-18",{"date":499,"type":22},"2026-10",{"name":39,"class":40},{"id":502,"slug":503,"hasResults":12,"nctId":504,"briefTitle":505,"officialTitle":505,"acronym":506,"eligibilityCriteria":507,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":508,"enrollmentInfo":509,"targetDuration":4,"studyType":23,"phases":511,"briefSummary":512,"conditions":513,"keywords":4,"overallStatus":111,"whyStopped":4,"lastUpdateSubmitDate":493,"lastUpdatePostDateStruct":515,"startDateStruct":517,"completionDateStruct":519,"leadSponsor":521,"locationsCount":239},"100552476","study-of-the-prevalence-of-diabetes-and-pre-diabetes-in-runion-island-100552476","NCT06473584","Study of the Prevalence of Diabetes and Pre-diabetes in Réunion Island","PREVADIABRUN","Inclusion Criteria:\n\n* Have lived in Réunion island for at least one year\n* Be aged between 18 and 75\n* Affiliated to or benefiting from a social security scheme\n* Free, informed and signed consent\n\nExclusion Criteria:\n\n* No main residence on the island or fixed address for at least one year on the island\n* Participation in experimental research\n* Pregnant women\n* Adults under guardianship or legal protection\n* Not understanding French","75 Years",{"count":510,"type":22},2000,[25],"In view of the new priority given to diabetes in Réunion and the implementation of an ambitious plan to combat the disease at regional level, which includes the identification and management of pre-diabetes, the need for up-to-date data on the extent of these 2 diseases (diabetes and pre-diabetes) has become essential.\n\nThese two diseases have known risk factors: age, overweight, obesity, high waist circumference, family history, hypertension, eating habits and physical activity, all of which form part of a risk score for developing diabetes: the Findrisk recommended by the Haute Autorité de Santé for identifying people at risk of diabetes. Given the specific population characteristics of Réunion compared with Finland, where this score has been validated, it would seem important to be able to measure these risk indicators in the population as a function of carbohydrate status in order to check that the proposed thresholds are appropriate for the population of Réunion.\n\nFinally, cardiovascular risk has been described as early as the pre-diabetes stage. Given the young age of onset of diabetes in Réunion and the high proportion of diagnoses of diabetes made following the occurrence of a cardiovascular complication, the study of the prognosis of carbohydrate status on the occurrence of complications using the social security information system will be offered on a voluntary basis to study subjects (via a probabilistic social security link).",[514],"Diabetes",{"date":516,"type":33},"2025-07-30",{"date":518,"type":33},"2025-04-02",{"date":520,"type":22},"2026-12",{"name":39,"class":40},{"id":523,"slug":524,"hasResults":12,"nctId":525,"briefTitle":526,"officialTitle":527,"acronym":528,"eligibilityCriteria":529,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":530,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":532,"conditions":533,"keywords":4,"overallStatus":111,"whyStopped":4,"lastUpdateSubmitDate":493,"lastUpdatePostDateStruct":537,"startDateStruct":538,"completionDateStruct":540,"leadSponsor":541,"locationsCount":120},"100549726","exploration-of-health-literacy-in-diabetes-in-reunion-island-and-france-100549726","NCT06437782","Exploration of Health Literacy in Diabetes in Reunion Island and France","Exploration of Health Literacy in Diabetes in Reunion Island and Metropolitan France","HLQ-Diabete","Inclusion Criteria:\n\nPatient with type 1, 2 or gestational diabetes taken care in hospital\n\nExclusion Criteria:\n\n* Patient unable to understand and respect study procedures\n* Patient with cognitive disorder\n* Patient with serious acute complication due to diabetes within 15 days before inclusion\n* Stroke history with neurologic consequences\n* Other specific types of diabetes : chronic calcific pancreatitis, iatrogenic, other secondary diabetes, rare monogenic or genetic diabetes due to insulin resistance",{"count":531,"type":22},1350,"The goal of this observational study is to identify the health literacy profile of diabetic patients in Reunion Island and France in order to obtain information to improve access to information, therapeutic education and to health service. The main question\\[s\\] it aims to answer \\[is\u002Fare\\]:\n\nParticipants will complete the Health Literacy Questionnaire (HLQ) once.",[534,535,536],"Diabetes type1","Diabetes Type 2","Diabetes, Gestational",{"date":516,"type":33},{"date":539,"type":33},"2025-04-17",{"date":157,"type":22},{"name":39,"class":40},{"id":543,"slug":544,"hasResults":12,"nctId":545,"briefTitle":546,"officialTitle":547,"acronym":548,"eligibilityCriteria":549,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":550,"targetDuration":4,"studyType":23,"phases":551,"briefSummary":552,"conditions":553,"keywords":4,"overallStatus":111,"whyStopped":4,"lastUpdateSubmitDate":493,"lastUpdatePostDateStruct":555,"startDateStruct":556,"completionDateStruct":558,"leadSponsor":560,"locationsCount":120},"100504709","evaluation-of-the-effectiveness-of-breathing-control-technique-on-long-covid-symptoms-at-the-reunion-university-hospital-100504709","NCT05851859","Evaluation of the Effectiveness of Breathing Control Technique on Long COVID Symptoms at the Reunion University Hospital","Randomized Controlled Trial Evaluating the Effectiveness of a Breathing Control Technique on Long COVID Symptoms at the Reunion University Hospital","COCO-Long'Run","Inclusion Criteria:\n\n* Patients over the age of 18,\n* living in Reunion and\n* having a diagnosis of Long COVID according to the World Health Organization (WHO) definition will be included in this study.\n* These patients must attest to their primary infection with Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and present a negative antigen test at the time of inclusion.\n\nExclusion Criteria:\n\nPatients:\n\n* with a chronic or disabling respiratory pathology preventing respiratory training (asthma, Chronic Obstructive Pulmonary Disease (COPD), active tuberculosis, pulmonary sequelae of COVID-19, etc.) practicing or having practiced a regular respiratory control technique (yoga, Cardiac coherence training, etc.) in the last 6 months\n* taking a beta-blocker, betamimetic, anti-arrhythmic, morphine, antidepressant treatment (Escitalopram)\n* having a pacemaker or severe heart disease\n* Current and known pregnancy or breastfeeding woman\n* with a cognitive deficit\n* under guardianship\u002Fcurators or under judicial protection",{"count":465,"type":22},[25],"Despite the controversy, on October 6, 2021, the World Health Organization (WHO) recognized Long Coronavirus disease (COVID) by officially defining it: \" symptoms appeared 3 months after the onset of the primary infection by the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), persisting for at least 2 months and which cannot be explained by any other condition \". Long COVID can affects any type of patient and has polymorphic and fluctuating symptoms over time.\n\nThe Reunion Island is a French overseas department located in the Indian Ocean accounting more than 860,000 inhabitants. It has recorded since March 11, 2020, nearly 491,825 cases of COVID-19 and 961 deaths of hospitalized patients. Reunion's population is multi-ethnic and younger than the metropolitan France's one. It also has a higher prevalence of obesity and type 2 diabetes, two serious form factors of COVID-19. This specific context makes this island a particular study site for Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and Long COVID.\n\nIn addition, some studies have confirmed the involvement of the autonomic nervous system (ANS) in the symptomatology of Long COVID and demonstrated that patients with a Long COVID present a dysfunction of their ANS which is objectified by a reduced Heart Rate Variability (HRV). The regulation of heart rate by the ANS is strongly favored by respiration. A regular slow and deep breathing training helps to adjust the baroreflex, which connect heart rate, breathing and blood pressure. The result of this training is an induced state called \"cardiac coherence\" (CC).\n\nThe investigator therefore hypothesize that respiratory training to CC could \"re-educate\" the ANS and durably improve the symptomatology of patients with Long COVID.",[554],"Long COVID",{"date":516,"type":33},{"date":557,"type":33},"2025-05-05",{"date":559,"type":22},"2027-04",{"name":39,"class":40},{"id":562,"slug":563,"hasResults":12,"nctId":564,"briefTitle":565,"officialTitle":566,"acronym":567,"eligibilityCriteria":568,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":569,"targetDuration":4,"studyType":23,"phases":571,"briefSummary":572,"conditions":573,"keywords":4,"overallStatus":111,"whyStopped":4,"lastUpdateSubmitDate":493,"lastUpdatePostDateStruct":576,"startDateStruct":577,"completionDateStruct":579,"leadSponsor":580,"locationsCount":239},"100369094","music-against-psychological-pain-in-suicide-100369094","NCT04085848","Music Against Psychological Pain in Suicide","A Controlled, Randomized Study Evaluating the Effecacy of Receptive Music Therapy on Psychological Pain in Suicidal Patients","MAPPS","Inclusion Criteria:\n\n* Patient with suicidal ideas, thoughts or surviving suicide attempt\n* Patient whose emergency somatic management lasted less than 48h\n* Patient who, according to the physician, is still in suicidal mood\n* Patient admitted in the psychiatric hospitalization unit of the Public Mental Health Establishment\n* Patient with voluntary admission and agrees to stay in hospital from 48h to 60h\n* Patient able to write and read in french\n* Patient affiliated to a social security scheme\n* Patient who gives his Informed consent before any procedure related to the study\n\nExclusion Criteria:\n\n* Patient with attempt suicide requiring a somatic care (intensive, surgery, gastric lavage...)\n* Patient with medical history of audiogenic and\u002For musicogenic epilepsy\n* Patient with major impairment of hearing function\n* Patient unable to support the headhset earphone\n* Patient with contra indication to BZD, hypnotics (Zopiclone) or requiring more sedative and\u002For psychotic drugs\n* Patient under guardianship or under judicial protection\n* Patient hospitalized at the request of a third party or ex officio",{"count":570,"type":22},264,[25],"This study compares the efficacy of music therapy associated with standard care versus the standard care alone on the psychological pain in suicidal patients.",[574,575],"Suicide, Attempted","Suicidal Ideation",{"date":516,"type":33},{"date":578,"type":33},"2020-02-25",{"date":237,"type":22},{"name":39,"class":40},{"id":582,"slug":583,"hasResults":12,"nctId":584,"briefTitle":585,"officialTitle":586,"acronym":587,"eligibilityCriteria":588,"healthyVolunteers":17,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":589,"targetDuration":591,"studyType":51,"phases":4,"briefSummary":592,"conditions":593,"keywords":595,"overallStatus":111,"whyStopped":4,"lastUpdateSubmitDate":599,"lastUpdatePostDateStruct":600,"startDateStruct":602,"completionDateStruct":604,"leadSponsor":606,"locationsCount":239},"100569989","epidemiology-and-risk-factors-for-injuries-in-beach-tennis-players-100569989","NCT06701409","Epidemiology and Risk Factors for Injuries in Beach Tennis Players","Epidemiology and Risk Factors for Injuries in Beach Tennis Players: a Prospective Cohort Study","EPITRAUMA-BT","Inclusion Criteria:\n\n* Player declaring that they train regularly in beach tennis (at least once a week)\n* At least 18 years old at the time of inclusion\n* Male or female\n* Able to read and understand French\n* Whether or not registered within a club\n* Not opposed to the research\n\nExclusion Criteria:\n\n* Protected adults (guardianship or curatorship) or those under court protection",{"count":590,"type":22},440,"12 Months","Beach tennis, a fast-growing sport since its creation in Italy in the 1970s, has rapidly gained in popularity, particularly in La Réunion sisland since 2000. However, despite its development, studies on beach tennis-specific injuries are rare, based on cross-sectional studies and therefore limited by temporal or memory bias. The need for prospective research is crucial if we are to gain a better understanding of the epidemiology of injuries and improve prevention and medical management.\n\nThe aim will be to determine the risk of injury among beach tennis players within a one-year national prospective cohort.",[594],"Sport Injury",[596,597,598],"Beach tennis","Injuries","National prospective cohort","2025-07-04",{"date":601,"type":33},"2025-07-08",{"date":603,"type":33},"2024-11-18",{"date":605,"type":22},"2025-12",{"name":39,"class":40},""]